Fundraising Fox

NMD Pharma

Aarhus, DK · Founded 2015 · 85 employees on LinkedIn · 6 known investors

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter> <parameter name="founders">[]

BiotechDeep TechHealthtechMedical Devices

Investors · 6

Jeito Capital✓ verifiedParis
Novo Holdings✓ verifiedCopenhagen · $1.1M – $54M
Roche Venture FundBasel · $648K – $3.2M
Inkefreported · 3 sourcesAmsterdam

Also in the syndicate · 2

Lundbeckfonden BioCapitalthe Roche Venture Fund

Funding

SEC filings, press & company announcements

$80M disclosed across 1 round · 2023

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
Uclahealth42 shared keywordsUCLA Health is an academic health system providing primary, immediate, and specialty medical care including cancer, neuroscience, transplant, orthopedics, cardiovascular, and children's care. It operates hospitals and clinics and trains medical students, with a network of locations in the Los Angeles area.
Osmosis37 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Companies competing with NMD Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness | The Manila Timesmanilatimes.net · Jul 2026NMD Pharma from Denmark secures €75M Series B to advance novel treatments for neuromuscular diseases - ArcticStartuparcticstartup.com · Nov 2023NMD Pharma Raises $81.3 Million to Advance Neuromuscular Disease Pipeline - Global Genesglobalgenes.org · Nov 2023NMD Pharma Raises €75 Million (~$80 million) in a Series B Financingglobenewswire.com · Nov 2023NMD bags €38M to run orphan neuromuscular disease trials | Fierce Biotechfiercebiotech.com · Mar 2018BioCentury - Neuromuscular play NMD raises EUR38M in series Abiocentury.com · Mar 2018

Frequently asked questions

What does NMD Pharma do?
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter> <parameter name="founders">[]
Who are NMD Pharma's investors?
NMD Pharma's investors include Jeito Capital, Novo Holdings, Roche Venture Fund, Inkef.
How much funding has NMD Pharma raised?
NMD Pharma has disclosed $80M raised across 1 round.
Where is NMD Pharma headquartered?
NMD Pharma is headquartered in Aarhus, DK.